CompletedNCT04969640Updated Mar 29, 2023

Role of Anterior Segment Optical Coherence Tomography in Infectious Keratitis

An observational study in Infective Keratitis, sponsored by Minia University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Minia University · Observational

Study type: Observational
Model: Other
Time perspective: Prospective
Enrollment: 23
Sex: All

Study summary

To evaluate the role of anterior segment optical coherence tomography in follow up of infectious keratitis and assessment of response to treatment.

Read the detailed description

50 patients with proven infectious keratitis clinically will be included in the study.

The following will be performed for all patients in initial visit and follow up:

Slit lamp examination and photography.
Visual acuity assessment.
Anterior segment optical coherence tomography.
1. The central corneal thickness (CCT) (extracted from pachymetry map),
2. Minimal corneal thickness (MCT) (extracted from pachymetry map)
3. Corneal thickness at the site of the lesion (CTL) (extracted from pachymetry map or the sum of STL+ CETL)
4. Stromal thickness at the center of the lesion (STL) stromal lesion (extracted from stromal map)
5. Corneal epithelial thickness over the stromal lesion (CETL) at the center of the lesion (extracted from epithelial map)

Conditions studied

Infective Keratitis

Browse trials for

Keratitis 108

In context

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

This study's enrollment of 23 is below the median of 105 across 31 observational studies indexed under Keratitis.

Browse Keratitis studies →

Lead sponsor

Minia University is the lead sponsor of 370 studies on the registry; 117 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Minia University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Any case with infective keratitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Any case with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.

Exclusion criteria

Exclusion Criteria:

Cases with healed infectious keratitis.
Cases presented from the start with severe corneal affection and melting.

Study design

Observational model: Other
Time perspective: Prospective
Enrollment: 23 participants (actual)
Patient registry: No

Groups and cohorts

infective keratitis
50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
Other: Optical coherence tomography

Interventions

OtherOptical coherence tomography
Anterior segment optical coherence tomography examination of corneas with infective keratitis

What researchers measure

Primary outcomes

criteria of lesion on optical coherence tomography
Localiztion, depth of infiltration area in microns
Time frame: 1 month
width of lesion on optical coherence tomography
width of infiltration in microns
Time frame: 1 month

Study locations

1 site

Faculty of Medicine
Minya, Egypt

References and documents

Individual participant data

Plan to share: Undecided — undecided

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Dec 2021, 5 months.

Of 16 observational studies under Keratitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 34. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered: Jun 25, 2021
First posted: Jul 21, 2021
StartActual: Jul 1, 2021
Primary completionActual: Dec 31, 2021
CompletionActual: Dec 31, 2021
Last update: Mar 29, 2023

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04969640
Lead sponsor: Minia University
Responsible party: Ahemd Abdelghany (Assistant professor, Minia University) — Principal investigator
First posted: Jul 21, 2021
Start date: Jul 1, 2021
Primary completion: Dec 31, 2021
Completion: Dec 31, 2021
Last update: Mar 29, 2023

Study contacts

Ahmed Abdelghany, ASS PROF

principal investigator · Minia University

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Keratitis →

Other studies from this sponsor

Minia University →

Start the discussion